[EN] PRMT5 INHIBITORS<br/>[FR] INHIBITEURS DE PRMT5
申请人:MERCK SHARP & DOHME
公开号:WO2020033282A1
公开(公告)日:2020-02-13
The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
本发明提供了化合物式(I)的化合物,或其药用可接受的盐,这些化合物是PRMT5抑制剂。
[EN] HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE PRMT5
申请人:ANGEX PHARMACEUTICAL INC
公开号:WO2020243178A1
公开(公告)日:2020-12-03
The present disclosure describes novel heterocyclic PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorders are also described.